The tumor microenvironment is a complex and dynamic landscape, comprising not just cancer cells but also stromal cells, immune cells, extracellular matrix components, and critically, the vasculature that supplies nutrients and oxygen. Tumor blood vessels are notoriously abnormal—they are structurally and functionally heterogeneous, often tortuous, irregular in diameter, and leaky. Such aberrations contribute to tumor progression and metastasis by fostering hypoxia and facilitating cancer cell dissemination. Crucially, this new research underscores that the phenotypic features of these abnormal vessels are not uniform across all patients, but rather show marked differences according to the patient’s age at diagnosis.

Using state-of-the-art imaging coupled with sophisticated histopathological techniques, the investigators profiled tumor vessel characteristics in colorectal cancer specimens from a wide age spectrum. These analyses revealed significant variations in vessel density, permeability, and molecular markers indicative of vessel maturity or immaturity when stratified by age groups. Younger patients tended to exhibit tumors enriched with more immature, proliferative vasculature, characterized by high microvessel density and greater expression of angiogenic markers. Conversely, older patients’ tumors displayed a phenotype suggestive of more mature, stable vessels, with distinct molecular signatures that may impact tumor behavior and response to therapy.

The implications of such findings are vast. Tumor angiogenesis—the formation of new blood vessels—is a central pillar in cancer progression and a primary target of several anti-cancer therapeutics. However, the efficacy of anti-angiogenic agents has been inconsistent in colorectal cancer, possibly due to the overlooked variable of patient age influencing vascular phenotype. The revelation that younger and older patients harbor fundamentally different tumor vessel architectures suggests a need for stratified treatment strategies, where age-specific vascular features inform personalized therapy selection.

Beyond therapeutic ramifications, the study also probes the biological mechanisms underlying age-associated vascular differences. The researchers hypothesize that age-related systemic changes in host physiology—such as alterations in circulating angiogenic factors, immune function, and extracellular matrix remodeling enzymes—may drive the observed tumor vessel heterogeneity. They further highlight the role of senescence and chronic inflammation, more prominent in older individuals, as modulators of the tumor microenvironment and vascular dynamics, potentially explaining the phenotypic vascular shifts with age.

Moreover, this research contributes to the growing body of evidence that tumors evolve in the context of their host’s physiological background. While genetics and cancer cell-intrinsic factors certainly shape tumor biology, this study emphasizes the critical influence of extrinsic factors like host age. Such perspectives challenge the conventional one-size-fits-all model of cancer treatment and advocate for a more holistic approach, acknowledging the tumor as a system embedded within a diverse human landscape.

The study also scrutinizes how vessel phenotype corresponds to clinical outcomes. Preliminary data suggest that younger patients with highly angiogenic, immature vessel-rich tumors may experience more aggressive disease courses. In contrast, older patients’ tumors with more normalized vasculature could manifest different metastatic patterns and responses to conventional chemotherapy or radiotherapy. These observations hint at the prognostic value of vascular profiling as a biomarker and raise the possibility of integrating vascular phenotype assessments into routine diagnostic pipelines.

Importantly, the paper does not shy away from discussing the methodological challenges involved in analyzing tumor vasculature, given its heterogeneity and dynamic nature. The authors advocate for continuing advancements in imaging technologies, including multiphoton microscopy and molecular imaging agents that can capture real-time vessel function and phenotype in vivo. Investments in such cutting-edge modalities will be crucial for translating these research findings into clinical practice.

In addition, the research team calls for larger, multi-institutional studies to validate their findings across more diverse populations and cancer stages. The interplay between tumor vessel phenotype and patient age might also vary with tumor genetic subtypes and molecular classifications known to exist within colorectal cancer. As such, a more granular stratification combining vascular, genetic, and demographic data represents an exciting frontier.

From a translational standpoint, the study invigorates interest in developing novel drugs targeting specific vascular phenotypes associated with particular age groups. For younger patients, agents targeting hyperproliferative angiogenesis may be more beneficial, whereas stabilizing the existing vasculature or modulating immune-vascular interactions may better serve older individuals. These insights could revolutionize standard care paradigms and improve survival and quality of life for colorectal cancer patients globally.

Lastly, these findings resonate with broader oncological research trends, where understanding the tumor microenvironment’s complexity and heterogeneity is key to overcoming drug resistance and relapse. The age-dependent variability in vessel phenotype highlighted here exemplifies the nuances that must be considered in next-generation cancer therapies and in the design of clinical trials.

In conclusion, this seminal work by Matsuda, Ugai, Miyahara, et al. represents a significant leap forward in cancer biology. By uncovering how colorectal cancer’s vascular landscape shifts with patient age, they provide a compelling rationale for integrating age as a critical factor in both research and clinical decision-making. As the field moves toward precision oncology, recognizing the tumor as an evolving ecosystem shaped by not only genetic but also host-related factors like age will be indispensable to crafting smarter, more effective treatments.

Subject of Research: Tumor vessel phenotype variations in the colorectal cancer microenvironment according to patient age at diagnosis.

Article Title: Tumor vessel phenotype in colorectal cancer microenvironment according to age at diagnosis.

Article References:
Matsuda, K., Ugai, S., Miyahara, S. et al. Tumor vessel phenotype in colorectal cancer microenvironment according to age at diagnosis. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03373-6

Image Credits: AI Generated

DOI: 25 March 2026

Extracellular vesicles have become a major focus of study because of their pivotal role in intercellular communication, particularly in the progression of cancers. Tumor-derived EVs can travel to distant sites in the body and prepare new environments conducive to cancer growth, a harbinger of metastasis. Until now, however, the precise molecular interactions enabling EVs to latch onto recipient cells and initiate these processes remained unclear. The latest research directly addresses this mystery, utilizing cutting-edge imaging techniques and molecular analyses to delineate the binding mechanisms underlying vesicle-cell interactions.

The study, published in the Journal of Cell Biology on April 30, 2025, zeroes in on small extracellular vesicles (sEVs) derived from multiple tumor cell lines. The research team, led by Professor Kenichi G.N. Suzuki of the Institute for Glyco-core Research and the National Cancer Center Research Institute in Japan, applied super-resolution microscopy and single-molecule imaging to track and characterize these vesicles at an unprecedented level of detail. This approach allowed them to identify the key molecular players responsible for the selective adhesion of sEVs to recipient cellular membranes.

Central to their findings is the identification of integrin heterodimers, which are protein complexes known for mediating cell adhesion and signaling. The research revealed that sEVs express specific integrin heterodimers associated with a tetraspanin protein called CD151. Tetraspanins, though small, are essential for the structural organization and function of EVs, guiding their formation and cargo sorting. The integrins linked to CD151 appear to be instrumental in targeting the vesicles to recipient cells through a particular extracellular matrix protein called laminin.

Laminin, a glycoprotein found abundantly within the extracellular matrix, is critical for maintaining cellular architecture and facilitating adhesion and migration. The study demonstrated that sEVs bind preferentially to laminin, rather than other matrix proteins such as fibronectin, highlighting a specificity in the interaction that goes beyond mere adhesion to extracellular components. This selective binding suggests a refined targeting mechanism through which EVs seek out and interact with recipient cells, possibly influencing where and how metastases develop in cancer progression.

Interestingly, the research also underscored the role of GM1, a glycolipid molecule that, together with the integrin heterodimers, forms the adhesive interface on the surface of sEVs. GM1 contributes to the binding affinity of vesicles for laminin, enhancing their ability to dock onto target cell membranes. The combined presence of CD151-associated integrins and GM1 is therefore necessary for effective vesicle attachment, which precedes the internalization or signaling events that influence recipient cell behavior.

Another notable aspect of the study pertains to adhesion-related proteins talin and kindlin, which are typically involved in activating integrins in the context of cell adhesion. Despite their association with EVs, talin and kindlin did not activate the integrins on the surface of sEVs in this new molecular context. This indicates a divergent mechanism of integrin activation on EVs compared to that in whole cells, adding a layer of complexity to how vesicles regulate their binding and signaling capabilities.

The implications of these findings extend beyond fundamental cell biology. Given that EVs are being increasingly investigated as biomarkers for disease and as vehicles for drug delivery, understanding how they selectively bind to specific cells opens new avenues for therapeutic intervention. By modulating these adhesion mechanisms — either blocking harmful tumor-derived EVs from seeding metastases or enhancing the targeting of therapeutic EVs to desired tissues — future treatments might achieve greater precision and efficacy.

Professor Suzuki emphasized the translational potential of this research, noting that while EVs have been explored extensively as disease biomarkers, the development of EV-based therapeutics has lagged in part due to incomplete knowledge of their targeting mechanics. The detailed elucidation of integrin heterodimer and GM1-mediated adhesion to laminin advances the field toward rational design of EV-modulating drugs and targeted delivery systems.

The multidisciplinary team, spanning institutions such as Gifu University and the National Cancer Center Research Institute, combined expertise in glycobiology, biophysics, and advanced microscopy to make these discoveries. Their rigorous approach leveraged state-of-the-art single-molecule resolution imaging to parse out subtle molecular interactions that were otherwise undetectable with conventional techniques, exemplifying how technological advances can unlock new biological insights.

The study received extensive support from numerous esteemed Japanese scientific foundations and agencies, reflecting its significance to both basic science and clinical biomedical research. This comprehensive support also underscores the urgency and broad interest in unraveling the complexities of EV biology as it relates to cancer metastasis and more.

As researchers delve deeper into the interplay of extracellular vesicles, integrin complexes, and extracellular matrix proteins like laminin, the prospect of manipulating these pathways offers exciting possibilities. Future strategies might include designing inhibitors that prevent metastatic EVs from docking at remote tissues or engineering EVs that can efficiently target malfunctioning cells to deliver therapeutic molecules, revolutionizing how diseases such as cancer are approached.

In sum, this new research marks a critical step forward in our understanding of the molecular mechanisms governing extracellular vesicle interactions with recipient cells. By delineating the roles of integrin heterodimers, the tetraspanin CD151, and GM1 in selective adhesion to laminin, the study provides a molecular blueprint that could inform the development of next-generation diagnostics and therapeutics targeting cancer metastasis and other pathologies involving intercellular communication.

—

Subject of Research: Cells
Article Title: Extracellular vesicles adhere to cells primarily by interactions of integrins and GM1 with laminin
News Publication Date: 30-Apr-2025
Web References: http://dx.doi.org/10.1083/jcb.202404064
Image Credits: Institute for Glyco-core Research
Keywords: Life sciences, Glycobiology, Membrane biophysics, Single molecule analysis, Cell biology, Adhesion signaling, Integrin signaling, High resolution imaging, Single molecule imaging